An attention-grabbing examine by Miquel Serra-Burriel et al. (2024) examines the impression of generics on drug costs in 8 high-income nations (Australia, Canada, France, Germany, Japan, Switzerland, the UK, and the US). The authors used IQVIA MIDAS information from 2011-2020 on 505 new originator medicine. They discovered that:

Value declines have been statistically important throughout the 8 years after patent expiration, with essentially the most fast value declines noticed within the US: 32% (95% CI, 24%-39%) in yr 1 after patent expiration and 82% (95% CI, 71%-89%) within the 8 years after patent expiration. Estimates for different nations ranged from a 64% decline in Australia to 18% in Switzerland within the 8 years after expiration. The associated fee-effectiveness simulation mannequin indicated that excluding generic entry might result in biased incremental cost-effectiveness ratios of 40% to -40%, relying on the state of affairs.

You may learn the complete article right here.